UNAIDS Executive Director Winnie Byanyima speaks during the Launch of HIV Prevention Project in Johannesburg, South Africa, ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Either we get ahead of this crisis or watch a generation of Americans be swept into the devastating grip of disease.

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

Despite Uganda's steady progress in reducing HIV infections and AIDS-related deaths, men remain disproportionately affected due to low uptake of antiretroviral treatment (ARVs), the Uganda AIDS ...

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Good morning and welcome, everyone, to today's press briefing from the U.S. Department of State's Africa Media Hub. Today, we are discussing the America First Global Health Strategy and the U.S.

To mark World AIDS Day, the Institute for Contemporary Arts will screen our film tackling the collapse of USAID funding ...

New diagnoses of HIV and syphilis have doubled in Florida since 2020. St. Lucie County has the highest rate of new HIV cases ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...